Skip to content
Agree.net – Lifestyle
Author:
Larimar Therapeutics
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
November 5, 2026
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
November 4, 2026
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
September 29, 2026
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
August 4, 2026
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
June 29, 2026
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
June 26, 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
May 14, 2026
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
April 30, 2026
BETMGM Q1 2026 BUSINESS UPDATE
April 14, 2026